01—Abstract
Summary
Summary of the 6-K filed May 2, 2025. Cited figures are marked; the original filing is the authoritative source.
James Hardie Industries plc (ASX / NYSE: JHX) filed a Form 6-K on May 2, 2025 containing a single exhibit: a letter to shareholders dated April 28, 2025, authorized by the Chair of the Board.
The letter addresses corporate governance commitments in connection with the proposed transaction with AZEK (the "Transaction"). The Board states it will continue to maintain an independent Chair and a majority of independent directors, and that it will continue to align management remuneration with shareholder value creation and hold an annual advisory vote on remuneration. The letter states that, upon completion of the AZEK transaction, two of the three AZEK directors added to the Board will be independent, and that the only non-independent directors will be the CEO and the then former AZEK CEO.
Anne Lloyd, an independent director, will remain Chair. The Board also states it has no intention to seek ASX Foreign Exempt Listing status and would hold a shareholder vote before any decision to change its ASX listing status. For investors, the filing is primarily a governance communication rather than a financial disclosure.
It states that management remuneration metrics will add measures such as cost and commercial synergy achievement, and that the annual Remuneration Report will detail how pay links to value delivered from the Transaction. The filing contains no financial results or transaction financial terms.
02—Key points
Key Highlights
- Letter to shareholders dated April 28, 2025, authorized by the Chair of the Board, responding to shareholder discussions on the AZEK transaction
- Board commits to maintaining an independent Chair (Anne Lloyd) and a majority of independent directors, consistent with the Board Charter
- Upon completion of the AZEK transaction, two of the three AZEK-nominated directors added to the Board will be independent
- Management remuneration will continue to be tied to shareholder value, with added metrics such as achievement of cost and commercial synergies in expected timeframes
- Annual advisory vote on the Remuneration Report will continue after the Transaction
- Board has no intention to seek ASX Foreign Exempt Listing status and would hold a shareholder vote before changing ASX listing status
- The Transaction is subject to risks including regulatory approvals, AZEK stockholder approval, financing, and the possibility synergies may not be realized
03—Questions
Frequently Asked Questions
Will James Hardie's board remain independent after the AZEK transaction?
The letter states the Board will continue to maintain an independent Chair and a majority of independent directors, as required by Section 6.1 of its Board Charter. Upon completion, two of the three AZEK directors added to the Board will be independent, and the only non-independent directors will be the CEO and the then former AZEK CEO.
Who will chair the Board after the transaction?
Anne Lloyd, an independent director, will remain Chair of the Board.
Will shareholders still vote on executive pay?
Yes. The company states it will continue to hold an advisory vote on its Remuneration Report each year, and it has voluntarily done so since 2005.
Is James Hardie planning to change its ASX listing status?
The Board states it has no intention to seek ASX Foreign Exempt Listing status, and it would hold a shareholder vote before making any decision to change its ASX listing status.
What are the main risks to the AZEK transaction?
The filing's cautionary statement cites risks including failure to obtain regulatory approvals or AZEK stockholder approval on a timely basis, financing access, the additional indebtedness the company would incur, possible failure to realize anticipated synergies, integration difficulties, and transaction-related litigation.
04—Continue